Yaz Birth Control: Side Effects, Risks, and Lawsuits
Understand Yaz birth control’s medical risks, FDA warnings, and how injured patients may pursue product liability lawsuits.
Yaz is a widely prescribed oral contraceptive that combines drospirenone (a synthetic progestin) with ethinyl estradiol (an estrogen). While it is effective at preventing pregnancy and treating conditions such as acne and premenstrual dysphoric disorder (PMDD), it has also been linked to serious safety concerns, including blood clots, stroke, and heart-related complications. These medical risks have triggered safety reviews, label changes, and extensive product liability litigation against its manufacturer.
This guide explains how Yaz works, its common and serious side effects, the role of the U.S. Food and Drug Administration (FDA), and the basic legal theories behind Yaz-related lawsuits so that patients can better understand both the health and legal implications.
What Yaz Is and How It Works
Yaz is a combined hormonal contraceptive pill that contains:
- Drospirenone – a progestin that has antimineralocorticoid and antiandrogenic activity, which may influence fluid balance and acne.
- Ethinyl estradiol – a synthetic estrogen used in many birth control pills to inhibit ovulation.
Together, these hormones prevent pregnancy primarily by:
- Suppressing ovulation (stopping the release of an egg)
- Thickening cervical mucus, making it harder for sperm to reach an egg
- Altering the uterine lining to reduce the chance of implantation
Beyond contraception, Yaz is approved in the United States for:
- Treatment of moderate acne in females who also desire oral contraception
- Treatment of premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS)
Common Side Effects Reported With Yaz
Like other combination birth control pills, Yaz frequently causes mild to moderate side effects. Many of these resolve after a few months of consistent use, although some users discontinue the drug due to discomfort.
Frequently Reported Mild Side Effects
Clinical trials and post-marketing experience have identified several common reactions:
- Headache or migraine
- Nausea or vomiting
- Irregular bleeding, spotting, or changes in menstrual flow
- Breast pain or tenderness
- Fatigue or low energy
- Mood changes, including irritability or low mood
- Weight changes or fluid retention
The Future of AI: Preventing a Big Tech Monopoly >
These effects are not unique to Yaz but are broadly associated with combined oral contraceptives. However, drospirenone’s unique hormonal profile has prompted closer scrutiny of some risks, particularly blood clots and changes in potassium levels.
Table: Selected Mild Side Effects of Yaz
| Side Effect | Typical Severity | When to Seek Care |
|---|---|---|
| Headache | Mild to moderate | If sudden, severe, or associated with vision or speech changes |
| Nausea / Vomiting | Often improves after first few cycles | If persistent, causing dehydration, or preventing pill use |
| Spotting / Irregular bleeding | Common during first months | If heavy, prolonged, or accompanied by severe pain |
| Breast tenderness | Mild to moderate | If associated with a lump, skin changes, or nipple discharge |
| Mood changes | Variable | If leading to significant depression, anxiety, or suicidal thoughts |
Serious Health Risks Linked to Yaz
Although most users experience only mild symptoms, some face rare but serious complications that can be life-threatening. Many Yaz lawsuits focus on these severe outcomes and whether patients were adequately warned.
Blood Clots and Venous Thromboembolism (VTE)
Combined hormonal contraceptives are known to elevate the risk of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Research has suggested that pills containing drospirenone may carry a higher VTE risk than some older progestins, although findings have varied between studies.
According to the FDA and independent reviews, the risk of blood clots is especially elevated:
- During the first 3–6 months of starting Yaz
- When restarting after a break in pill use
- In women with additional risk factors, such as obesity, smoking, or certain inherited clotting disorders
Potential consequences of a clot include:
- Deep vein thrombosis in the legs, which may cause pain, swelling, or redness
- Pulmonary embolism, when a clot travels to the lungs and can cause sudden shortness of breath, chest pain, or collapse
- Stroke or heart attack if clots affect arteries in the brain or heart
Cardiovascular and Cerebrovascular Events
Stroke and heart attack are rare in otherwise healthy young women, but combination pills such as Yaz can increase the risk, particularly in users who:
- Are over age 35 and smoke cigarettes
- Have uncontrolled high blood pressure or diabetes
- Have a history of migraine with aura
- Have certain inherited cardiovascular conditions
The U.S. prescribing information for Yaz includes a boxed warning advising that women over 35 who smoke should not use estrogen-containing contraceptives due to increased risks of serious cardiovascular events. This warning mirrors that applied to other combined pills, but Yaz litigation has argued that drospirenone-specific clot risks were not initially emphasized enough.
Elevated Potassium (Hyperkalemia)
Drospirenone has effects similar to a mild diuretic that conserves potassium. For most users, this is not clinically significant. However, in women with kidney, liver, or adrenal disease—or those taking other medicines that increase potassium—Yaz can raise potassium to dangerous levels.
Severe hyperkalemia may cause:
- Heart rhythm disturbances or palpitations
- Muscle weakness or paralysis
- Sudden cardiac arrest in extreme cases
Other Serious Concerns
Additional serious but less common issues reported with combined oral contraceptives, including Yaz, include:
- Gallbladder disease or gallstones
- Liver problems such as hepatic adenomas (rare benign tumors)
- Severe allergic reactions
Not all such events are conclusively caused by Yaz, and many remain rare. However, clustered reports and some epidemiologic studies led regulators to require more prominent warnings and risk discussions.
FDA Monitoring and Safety Communications
The U.S. Food and Drug Administration continuously reviews safety data from clinical trials, post-marketing surveillance, and observational studies. For drospirenone-containing contraceptives like Yaz, the FDA has:
- Reviewed multiple epidemiologic studies assessing blood clot risks compared to other pills
- Required updates to prescribing information to highlight possible increased VTE risk with drospirenone-containing products
- Encouraged clinicians to evaluate individual risk factors (such as smoking status and obesity) before prescribing
These actions do not mean that Yaz is unsafe for all users; rather, they indicate that risk-benefit decisions must be individualized, and patients must be fully informed of known and suspected risks.
Why Patients Have Filed Yaz Lawsuits
Many individuals allege they were harmed by Yaz and that the manufacturer failed to give adequate warnings or properly communicate the extent of certain risks. While specific cases vary, common themes in product liability lawsuits include:
- Failure to warn – Claims that risk information about blood clots, stroke, or other complications was not clear, prominent, or timely.
- Design defect – Allegations that drospirenone-containing formulations pose higher avoidable risks than feasible alternative designs.
- Misrepresentation or misleading marketing – Concerns that promotional materials emphasized benefits such as acne control and mood improvement while downplaying serious side effects.
Some plaintiffs allege they experienced severe outcomes such as pulmonary embolism, deep vein thrombosis, stroke, or heart attack after taking Yaz, leading to long-term disability, medical expenses, or the loss of a loved one. These cases often seek compensation for:
- Past and future medical bills
- Lost wages or diminished earning capacity
- Pain and suffering
- Wrongful death damages (for surviving family members)
Elements of a Yaz Product Liability Claim
To pursue a civil claim based on Yaz-related injuries, a plaintiff generally must prove several elements under product liability law. The exact legal standards differ by state, but key concepts often include:
1. Defect or Inadequate Warning
The plaintiff must show that Yaz was defective in one of the legally recognized ways, such as:
- A design defect in how the drug was formulated
- A manufacturing defect in how a particular batch was produced
- An inadequate warning or failure to disclose known or reasonably knowable risks
2. Causation
The plaintiff must link the defect or inadequate warning to the injury. This often requires expert medical testimony to explain how Yaz could have contributed to a specific adverse event (for example, a blood clot or stroke) and to rule out other primary causes.
3. Damages
Finally, the plaintiff must demonstrate actual harm, which may include economic losses (such as medical bills) and non-economic harm (such as pain, disability, or loss of enjoyment of life).
Evidence Commonly Used in Yaz Litigation
Yaz cases often rely on a combination of regulatory, scientific, and medical evidence, such as:
- FDA communications, boxed warnings, and updated prescribing information
- Published epidemiologic studies comparing drospirenone-containing pills with other contraceptives
- Internal company documents obtained during discovery in litigation
- Medical records documenting a patient’s use of Yaz and subsequent injury
- Expert opinions from physicians and pharmacology or epidemiology specialists
These materials are used to show what risks the manufacturer knew or should have known about, when they became aware of those risks, and whether their warnings and marketing were adequate in light of that knowledge.
Should You Stop Taking Yaz?
Decisions about starting or stopping a prescription medication should always be made jointly with a healthcare professional. Regulatory authorities such as the FDA and clinical guidelines do not generally recommend that all women stop using Yaz; instead, they emphasize individual risk assessment and informed consent.
You may wish to discuss alternatives with your clinician if you:
- Have a history of blood clots, stroke, heart disease, or certain clotting disorders
- Smoke cigarettes, especially if you are 35 or older
- Have uncontrolled high blood pressure, migraines with aura, kidney disease, or conditions that affect potassium balance
- Develop warning signs such as sudden leg pain or swelling, chest pain, severe headache, or vision changes
Non-estrogen forms of contraception—such as progestin-only pills, intrauterine devices (IUDs), or implants—may be recommended for higher-risk patients, but the choice depends on individual medical history and preferences.
Practical Steps if You Believe Yaz Harmed You
If you suspect that Yaz caused a serious side effect or injury, consider taking the following steps promptly:
- Seek immediate medical care for any emergency symptoms such as chest pain, shortness of breath, severe headache, sudden weakness, or vision changes.
- Document your history of Yaz use, including dates, dosage, and any changes in formulation or brand.
- Obtain copies of your medical records related to diagnosis, treatment, and hospitalization.
- Report the event to the FDA’s MedWatch program; patient reports help regulators monitor drug safety signals.
- Consult a product liability attorney with experience in pharmaceutical cases to evaluate potential legal options.
There are often strict time limits (statutes of limitation) for filing a claim, which vary by state and type of injury. Speaking with legal counsel early can help protect your rights.
Frequently Asked Questions (FAQs)
Q: Is Yaz more dangerous than other birth control pills?
A: All combined hormonal contraceptives increase the risk of blood clots compared with not using them. Some observational studies and regulatory reviews have suggested that drospirenone-containing pills, including Yaz, may carry a somewhat higher clot risk than some older progestins, though findings are not uniform across all studies. Because of this, labels have been strengthened and clinicians are urged to carefully assess individual risk factors.
Q: What are the classic warning signs of a blood clot while taking Yaz?
A: Symptoms that warrant urgent medical evaluation include sudden swelling, pain, or warmth in one leg (possible deep vein thrombosis); abrupt shortness of breath or chest pain (possible pulmonary embolism); sudden severe headache, weakness on one side, trouble speaking, or vision loss (possible stroke); and crushing chest pain or pressure (possible heart attack).
Q: If I am a smoker, can I safely take Yaz?
A: The prescribing information for Yaz and other estrogen-containing pills carries a boxed warning stating that women over 35 who smoke should not use these products due to a sharply increased risk of serious cardiovascular events. Even younger smokers may have elevated risks. Healthcare professionals typically advise smokers to consider non-estrogen contraceptive methods.
Q: Does experiencing a mild side effect mean I have a lawsuit?
A: Not usually. Mild side effects such as nausea, spotting, or breast tenderness are common and are disclosed in prescribing information. Product liability claims typically focus on severe, unexpected harms—such as major blood clots, stroke, or death—and on allegations that the manufacturer failed to provide adequate warnings or engaged in misleading marketing. Only an attorney can evaluate whether your specific situation might support a claim.
Q: Can I switch from Yaz to another form of contraception on my own?
A: It is important not to stop or switch prescription contraception without speaking to a healthcare professional. Abruptly stopping Yaz without starting an alternative increases the risk of unintended pregnancy, and some medical conditions (like severe acne or PMDD) may flare when therapy is stopped. A clinician can help plan a transition to another pill, a progestin-only method, or a long-acting reversible contraceptive in a way that minimizes gaps in protection.
References
- YAZ (drospirenone and ethinyl estradiol) Prescribing Information — U.S. Food and Drug Administration / Bayer Healthcare Pharmaceuticals. 2012-04-10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021676s012lbl.pdf
- Drospirenone and ethinyl estradiol (oral route) — Mayo Clinic. 2023-08-01. https://www.mayoclinic.org/drugs-supplements/drospirenone-and-ethinyl-estradiol-oral-route/description/drg-20061917
- Yaz: Side effects and how to manage them — MedicalNewsToday. 2023-11-13. https://www.medicalnewstoday.com/articles/drugs-yaz-side-effects
- Yaz: Uses, Side Effects, Dosage, and More — Healthline. 2023-05-09. https://www.healthline.com/health/drugs/yaz
- YAZ® Consumer Medicine Information — Medsafe (New Zealand Medicines and Medical Devices Safety Authority). 2022-09-15. https://www.medsafe.govt.nz/consumers/cmi/y/yaz.pdf
Similar Articles
Read full bio of medha deb
